Genmab — Maj 2020
-
det kommer jo anpå hvor lang tid Roche er på hold
-
1.805
-
Mon hatten skal rundt Helge?
-
Interessant oplysning fra the new kid on the block: they've amended all company-sponsored clinical studies of daratumumab to allow patients to switch from the IV formulation to the subcutaneous formulation if there is a patient and physician desire to do so.
-
Jyske Bank raises target price on Genmab to 1825 from 1725
-
E L I think mosunetuzumab is mono https://www.roche.com/investors/updates/inv-update-2019-12-07.htm
-
i think there are more trials. i am just wondering since Jan said "better treatment of CLL potentially in better and more efficacious regimes, which are without chemotherapy, so combinations of epcoritamab and potential small-molecule drugs, are of high, high interest to us and potential partners"
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind